All India Institute of Medical Sciences, New Delhi, India, Mayo Clinic College of Medicine, Rochester, Minnesota, USA

Peyronie's disease is a relatively common condition affecting men with estimates of current prevalent rates ranging from 1 to 4%. However, it has no clear management protocols, primarily due to a lack of high quality evidence in support of treatment options. This article aims to review the recent published literature on management strategies for Peyronie's disease.

Intralesional interferon therapy has shown to result in significant improvement in Peyronie's disease plaques and curvature. Intralesional verapamil and extracorporeal shock wave therapy may help retard the progression of disease. Acellular, extracellular matrix-based grafts provide durable long-term satisfactory results in men requiring complex reconstruction.

Further clinical trails are warranted to evaluate the role of oral systemic therapies for early Peyronie's disease. Injection therapy, primarily with interferon, seems to be the most promising treatment for early stage Peyronie's disease. For men with established plaques, surgery using either plication or grafts forms the mainstay. There is an increasing trend to use autologous graft material that is commercially available and avoids donor site complications from autologous tissue.

Written by:
Kumar R, Nehra A   Are you the author?

Reference:
Curr Opin Urol. 2009 Sep 8. (Epub ahead of print)

PubMed Abstract
PMID: 19741538

UroToday.com Peyronie's Disease Section

Please log-in or register in order to submit comments.

Powered by AkoComment!